Bone marrow purging by photodynamic treatment in children with acute leukemia: cytoprotective action of amifostine.

Abstract

In order to evaluate the combined effect of Amifostine and Merocyanine 540 during photoirradiation in neoplastic cells, bone marrow cells from children with acute leukemia (AL), age-matched controls as well as HL-60 cell line were studied. Cell suspensions were incubated with Amifostine, then with MC 540 and they were subsequently exposed to different irradiation doses by Argon Laser 514 nm. Cell survival was estimated by trypan blue supravital stain following a 24-h incubation. The leukemic cell line was studied in continuous liquid cell cultures for 4 weeks. The survival of normal bone marrow progenitors has been estimated by colony formation assay in methylcellulose cultures. Our results showed that Amifostine enhances the photokilling effect of MC 540 on leukemic cells and significantly protects bone marrow nucleated and committed progenitors (BFU-E and CFU-GM) from children with AL under chemotherapy. In conclusion, Amifostine seems to be a promising cytoprotective agent in the clinical use of purging with MC 540 mediated phototherapy.

• Authors: V Danilatou, E Lydaki, H Dimitriou, T Papazoglou, M Kalmanti
• Journal: Leukemia research (Leuk Res) Vol. 24 Issue 5 Pg. 427-35 (May 2000) ISSN: 0145-2126 [Print] England
• PMID: 10785265 (Publication Type: Journal Article)

Chemical References

• Photosensitizing Agents
• Pyrimidinones
• Radiation-Protective Agents
• merocyanine dye
• Amifostine

Topics

• Amifostine (pharmacology, therapeutic use)
• Bone Marrow (drug effects, pathology)
• Bone Marrow Purging
• Cell Survival (drug effects)
• Drug Therapy, Combination
• HL-60 Cells
• Humans
• Photochemotherapy
• Photosensitizing Agents (pharmacology, therapeutic use)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (pathology, therapy)
• Pyrimidinones (pharmacology, therapeutic use)
• Radiation-Protective Agents (pharmacology, therapeutic use)